Fig. 2 The mean VAS pain score and JOA lower back pain score changes in groups A and B. Data are expressed as mean ± SD. The decrease in VAS and the increase in JOA CYT387 cost scores were significant between groups A and B at 6, 12, and 18 months, respectively. (*p < 0.05, ★p < 0.01) VAS visual analog scale, JOA Japanese Orthopedic Association In group B, three patients had intolerable side effects and needed to change antiresorptive agents.
The mean VAS score was 8.13 ± 0.95 (range, 6–10) prior buy INCB28060 to treatment and 4.09 ± 1.31 1 months after PVP plus antiresorptive agent treatment. The mean VAS score was 3.27 ± 1.42 after 6 months, 2.95 ± 1.56 after 12 months, and 3.14 ± 1.58 (range, 1–6) after 18 months of PVP plus antiresorptive treatment (Fig. 2). The VAS scores of all patients in group B were >0, and two patients were analgesic free at 18 months of follow-up. The VAS Semaxanib scores of the two groups were significantly different at each time point, beginning at 6 months (p < 0.05). The mean JOA score in group A was 9.95 ± 4.02 prior to treatment and 18.59 ± 3.28 after 1 month of treatment. A significant increase in the
mean JOA score occurred after 1 month of treatment with teriparatide. The mean JOA score was 21.23 ± 2.62 (range, 16–24; p = 0.001) after 6 months and 24.18 ± 2.79 after 12 months of teriparatide treatment and then increased to 26.00 ± 2.51 (range, 17–29) after 18 months of teriparatide treatment (p = 0.001, all the differences between baseline and 6 months, 6 months and 12 months, and 12 months and 18 months were Cobimetinib significant). Three patients had full JOA scores, and four were analgesic free at 20 months of follow-up. In group B, the mean JOA score was 11.59 ± 3.46 prior to treatment, 17.32 ± 3.41 after 1 month of treatment, 18.09 ± 2.58
(range, 16–24; p = 0.001) after 6 months of vertebroplasty combined with an antiresorptive treatment, and 19.41 ± 2.68 after 12 months of teriparatide treatment. After 18 months of treatment, the mean JOA score did not increase, but decreased slightly to 18.80 ± 3.33 (range, 13–26). No patient had a full JOA score, and two were analgesic free at 20 months of follow-up. The mean JOA scores of the two groups were significantly different at each time point, beginning at 6 months (p < 0.05). The VAS score in group A was significantly lower than that in group B after 6 months of treatment (p = 0.003). Similarly, the JOA score in group A was significantly higher than in group B after 6 months (P = 0.000). In group A (teriparatide group), only one patient developed a new-onset adjacent compression fracture after teriparatide treatment. That patient was a 72-year-old woman with severe osteoporosis (T-score, −4.30) who underwent vertebroplasty for an L2 compression fracture. A new-onset adjacent VCF at L3 occurred 78 days after PVP. The patient was started on teriparatide treatment on the day the new-onset fracture was diagnosed.